Why PepGen Inc.’s (PEPG) Stock Is Up 6.49%
As of Wednesday, October 07, PepGen Inc.’s PEPG share price has surged by 6.49%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Commentary & Analysis
Why PepGen Inc.’s (PEPG) Stock Is Down 5.58%
As of Thursday, October 01, PepGen Inc.’s PEPG share price has dipped by 5.58%, which has investors questioning if this is right time to buy.Michael Rose
Why PepGen Inc.’s (PEPG) Stock Is Up 6.62%
As of Wednesday, September 30, PepGen Inc.’s PEPG share price has surged by 6.62%, which has investors questioning if this is right time to sell.Michael Rose
Why PepGen Inc.’s (PEPG) Stock Is Down 5.40%
As of Tuesday, September 29, PepGen Inc.’s PEPG share price has dipped by 5.40%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why PepGen Inc.’s (PEPG) Stock Is Down 5.87%
As of Wednesday, September 23, PepGen Inc.’s PEPG share price has dipped by 5.87%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | PEPG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $160.0 | $241.3 | 25% |
|
| Shares Out (Mil) | 69.2 | 53.9 | 55% |
|
| Institutional Ownership | 99.4% | 93.1% | 88% |
|
| Float (Mil) | 36.1 | 41.4 | 40% |
|
| Beta | 1.89 | 0.95 | 90% |
|
| Avg Daily Volume (000s) | 986 | 646 | 69% |
|
| Price Change (52-week) |
(55.0%) | 49.4% | 16% |
|
| Growth | PEPG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | (116.2%) | (10.1%) | 1% |
|
| EPS (5yr) | 14.7% | 15.8% | 55 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (48.6%) | (15.7%) | 7% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | ($0.267) | ($1.072) | ($1.037) | |
| Month Ago EPS | ($0.267) | ($1.072) | ($1.037) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.275) | ($1.077) | ($1.078) | |
| Year/Year Chg | 3.9% | (49.5%) | (49.9%) | |
| Financials | PEPG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($72) | ($44) | 14% |
|
| EPS (TTM) | ($1.190) | ($1.600) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($69) | ($33) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($12) | $2 | 29% |
|
| Long-Term Debt (Q1) (Mil) | $13 | $4 | 30% |
|
| Enterprise Value (Q1) (Mil) | $100 | $174 | 21% |
|
| Valuation | PEPG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.34 | 2.33 | 36% |
|
| P/E | na | 18.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | PEPG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (59.1%) | (47.7%) | 10% |
|
| ROE | (75.5%) | (54.6%) | 11% |
|
| Liabilities to Assets | 15.5% | 29.3% | 10% |
|
| F-Score | 3 | 2 | 18% |
|
PepGen Inc. did not pass any screens on 10/6/2026.
